#USA #New York #Everest Group #ACTO #Pharmaceutical Technology

ACTO Recognized as a Leading Pharmaceutical Technology Provider in 2026

On September 14, 2026, ACTO announced its inclusion in the prestigious Top 50™ Pharmaceutical Technology Providers list compiled by the Everest Group. This recognition underscores ACTO's significant contributions to operational excellence in the life sciences, particularly through its integration of human intelligence with empathetic AI.

The Everest Group’s Top 50™ ranking is a globally recognized assessment highlighting key technology providers that drive innovation within the pharmaceutical value chain. This list not only reflects a comprehensive evaluation of numerous factors influencing the industry but also emphasizes the rise of agent-based AI, cloud-native capabilities, and the importance of strategic partnerships in the pharmaceutical sector.

As pharmaceutical companies increasingly invest in technologies designed to enhance business and medical outcomes, the demand for platforms that support omnichannel strategies, unify customer data, and personalize engagement with healthcare professionals is on the rise. Durga Ambati, vice president at Everest Group, stated, “Pharmaceutical companies are shifting from isolated workflow digitization to connected, AI-driven execution. They seek technology platforms capable of integrating fragmented data and systems while ensuring the necessary governance, traceability, and compliance required in regulated environments.”

The Role of ACTO in Advancing Pharmaceutical Technology

ACTO has carved out a unique position in the life sciences sphere through continuous investments in AI technology. Their intelligent platform offers knowledge assistance, simulated coaching, and automated workflows through agents. Additionally, ACTO’s seamless integrations with major platforms like Veeva and Salesforce further solidify its standing within the broader commercial technology ecosystem. These benefits have undoubtedly contributed to its selection as one of the top pharmaceutical technology providers for 2026.

The report also notes the swift progression towards agent-based AI, where the pharmaceutical technology landscape is shifting towards goal-oriented agents that can orchestrate multi-step workflows across various systems under stringent control. This transition is primarily evident in both commercial and medical domains, aligning perfectly with ACTO’s strategic goals.

ACTO's Commitment to Innovation

Founded with a sole focus on life sciences, ACTO's expertise in the intricate landscape of pharmaceutical processes, regulatory realities, and industry dynamics manifests in their native AI platform. This platform is designed to support customer-facing professionals, enhancing their efficacy and impact. Parth Khanna, co-founder and CEO of ACTO, expressed gratitude for the recognition, stating, “Our exclusive commitment to life sciences has allowed us to gain deep insights and knowledge in this unique sector. Our agent-based AI solutions are built to elevate human intelligence while accelerating execution.”

The Top 50™ evaluation comprises a weighted composite score based on four key parameters: Market Adoption and Scale (45%), Innovation, Investments and Partnerships (30%), Delivery of Value and Outcomes (15%), and Customer Coverage and Geographic Reach (10%). This rigorous evaluation criterion ensures that only the most capable and innovative companies are recognized.

Looking Ahead

As ACTO continues to redefine how therapies reach patients post-regulatory approval, they invite interested parties to learn more about their AI-driven Field Excellence platform at industry events, including the Fierce Pharma Week in Philadelphia, and on their official website. ACTO’s mission is to enhance operational efficiency and client engagement in the life sciences sector while upholding the highest industry standards.

For the complete Everest Group report detailing the Top 50™ Pharmaceutical Technology Providers for 2026 and to discover more about how ACTO is transforming operational excellence, you can visit their website or follow them on LinkedIn for the latest updates.